A Phase 1, Randomized, Single-Blind, Single-Dose, Parallel-Group Study Evaluating Pharmacokinetic Equivalence of ABP 215 with EU-Authorized Bevacizumab in Healthy Adult Japanese Men

Trial Profile

A Phase 1, Randomized, Single-Blind, Single-Dose, Parallel-Group Study Evaluating Pharmacokinetic Equivalence of ABP 215 with EU-Authorized Bevacizumab in Healthy Adult Japanese Men

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 18 Oct 2017 Primary endpoint (Maximum observed serum concentration (Cmax)-Pharmacokinetic Equivalence) has been met, according to results presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Primary endpoint (Area under the serum concentration-time curve from time 0 to infinity (AUCinf)-Pharmacokinetic Equivalence) has been met, according to results presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top